返回 
加入收藏
沙库巴曲缬沙坦对比贝那普利用于围绝经期高血压患者的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 沙库巴曲缬沙坦对比贝那普利用于围绝经期高血压患者的临床观察 |
| TITLE： | Clinical observation of sacubitril/valsartan versus benazepril in perimenopausal hypertensive patients |
| 摘要： | 目的 比较沙库巴曲缬沙坦与贝那普利用于围绝经期高血压患者的降压效果及对心室重构、炎症纤维化的影响。方法回顾性收集我院2023年1月1日至2024年12月30日收治的206例围绝经期高血压患者资料，按用药的不同分为贝那普利组（105例）和沙库巴曲缬沙坦组（101例）。贝那普利组患者给予盐酸贝那普利片，沙库巴曲缬沙坦组患者给予沙库巴曲缬沙坦钠片，所有患者均治疗6个月。观察并比较两组患者治疗前后的血压（收缩压、舒张压）及血压达标情况、心脏超声指标（左室射血分数、左室质量指数、相对壁厚、二尖瓣口舒张早期峰值血流速度/二尖瓣环舒张早期峰值运动速度）、炎症纤维化相关指标（超敏C反应蛋白、单核细胞与淋巴细胞比值、中性粒细胞与淋巴细胞比值）及不良反应（低血压、高钾血症、血管性水肿）发生情况。结果沙库巴曲缬沙坦组患者的血压达标率显著高于贝那普利组（P＜0.05）。治疗后，两组患者的血压、心脏超声指标（左室射血分数除外）、炎症纤维化相关指标水平均显著低于同组治疗前，且沙库巴曲缬沙坦组显著低于同期贝那普利组（P＜0.05）。两组患者低血压、高钾血症、血管性水肿的发生率及不良反应总发生率比较，差异均无统计学意义（P＞0.05）。结论与贝那普利比较，沙库巴曲缬沙坦能更有效地控制围绝经期高血压患者的血压，逆转心室重构及抑制炎症纤维化，且二者的安全性相当。 |
| ABSTRACT： | OBJECTIVE To compare the antihypertensive efficacy of sacubitril/valsartan versus benazepril in patients with perimenopausal hypertension， as well as their impacts on ventricular remodeling and inflammatory fibrosis. METHODS A total of 206 perimenopausal hypertensive patients in our hospital from January 1， 2023 to December 30， 2024 were retrospectively included.These patients were enrolled and divided into benazepril group （105 cases） and sacubitril/valsartan group （101 cases）. Benazepril group received Benazepril hydrochloride tablet， and sacubitril/valsartan group received Sacubitril valsartan sodium tablet. All patients were treated for 6 months. The blood pressure（systolic blood pressure and diastolic blood pressure） and blood pressure control status before and after treatment， echocardiographic indicators （left ventricular ejection fraction， left ventricular mass index， relative wall thickness， and early-diastolic peak transmitral flow velocity/early-diastolic peak velocity of the mitral annulus）， inflammatory fibrosis related indicators（high-sensitivity C-reactive protein，ratio of monocytes to lymphocytes，and ratio of neutrophils to lymphocytes）， as well as the occurrence of adverse reactions（hypotension，hyperkalemia，and angioedema） were observed in both groups before and after treatment. RESULTS The blood pressure control rate was significantly higher in the sacubitril/valsartan group than in benazepril group （ P ＜0.05）. After treatment， the blood pressure， echocardiographic indicators（except for left ventricular ejection fraction） ，and inflammatory fibrosis related indicators were significantly lower than those before treatment within the same group， and the sacubitril/valsartan group were significantly lower than the benazepril group （ P ＜0.05）. There were no statistically significant differences in the incidence of hypotension， hyperkalemia， angioedema， and overall adverse drug reactions between the two groups （ P ＞0.05）. CONCLUSIONS Compared with benazepril， sacubitril/valsartan provides superior blood-pressure control， reverses ventricular remodeling， attenuates inflammatory fibrosis in perimenopausal hypertensive patients， while maintaining a similar safety profile. |
| 期刊： | 2026年第37卷第04期 |
| 作者： | 张晓霞；邵柏林；周英坤；张占海；李志英 |
| AUTHORS： | ZHANG Xiaoxia，SHAO Bolin，ZHOU Yingkun，ZHANG Zhanhai，LI Zhiying |
| 关键字： | 沙库巴曲缬沙坦；贝那普利；围绝经期；高血压；心室重构；炎症纤维化 |
| KEYWORDS： | sacubitril/valsartan； benazepril； perimenopause； hypertension； ventricular remodeling； inflammatory fibrosis |
| 阅读数： | 0 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
